Bausch + Lomb Will Present New Scientific Data During the ASCRS Annual Meeting

Bausch + Lomb announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place from April 22-26, 2022 in Washington, DC. The presentations will include results from the first of two pivotal phase 3 trials of the investigational treatment, NOV03 (perfluorohexyloctane), as well as from several studies involving the company's surgical technologies.  

The results of the phase 3 trial (GOBI) evaluating NOV03, which is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD), will be featured in a podium presentation entitled, "Efficacy of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: The Gobi Study." DED is one of the most common ocular surface disorders causing discomfort for millions of Americans, with MGD playing a key role in the development of the disease.^1,2

The remaining podium and poster presentations will feature the results of studies evaluating the enVista MX60E IOL, enVista toric MX60ET IOL, Crystalens AO IOL, Stellaris Elite vision enhancement system, ClearVisc dispersive ophthalmic viscosurgical device and the cloud-based eyeTELLIGENCE digital integration platform, which is available exclusively on the Stellaris Elite.

The full schedule of scientific poster and clinical presentations, as well as the list of promotional education events is as follows: 

Scientific Podium Presentations

Saturday, April 23

• "Correction of Low Levels of Astigmatism during Cataract Surgery with the Glistening-Free Monofocal Toric IOL with Enhanced Delivery Optics." Stephenson et al. 
• "Influence of Lens Position on Level of Negative Dysphotopsia Experienced by Patients After Cataract Surgery." Packer et al. 
• "Rotational Stability of Aberration-Neutral Hydrophobic Toric IOL with Enhanced Delivery Characteristics." Wiley et al.
• "Randomized Bilateral-Eye Comparison of clinical outcomes Between 2 Novel Preloaded Hydrophobic Aspheric Monofocal IOLs." Shultz et al. 

Sunday, April 24

• "Efficacy of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: The Gobi Study." Tauber et al. 
• "Incidence of Clinically Significant Lens Rotations in Toric IOL Platforms: A Retrospective Consecutive Case Series." Hu et al.
• "Patient Reported Outcomes Using CatQuest-9SF Questionnaire After Implantation of Glistening-Free, Toric IOL with Aberration-Neutral Optics." Liang et al. 
• "Phacoemulsification in 325 Consecutive Eyes with Cataract Blindness: Novel Surgical Classification and Techniques." Peters et al.

Monday, April 25

• "Comparison of Visual Outcomes of Plate-Haptic Accommodating IOL versus Non-Diffractive Extended Vision IOL."  Liang et al. 
• "Ex Vivo Comparative Evaluation of a New Dispersive Ophthalmic Viscosurgical Device." Stephenson et al. 

Scientific Poster Presentations

• "Implantation of Aberration-Neutral, Hydrophobic Toric IOL with Enhanced Optic Delivery for the Correction of Moderate to High Astigmatism." Sadri et al. 
• "Visual and Refractive Outcomes with an Aberration-Neutral Hydrophobic Toric IOL with Enhanced Delivery Characteristics." Sadri et al. 

References